GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2012

Santhera Regains Global Rights to Parkinson Disease Drug Fipamezole from Ipsen

  • Santhera Pharmaceuticals and Ipsen have amended their existing agreement for the development and commercialization of Santhera’s clinical-stage Parkinson disease drug, fipamezole. Ipsen is returning to Santhera rights to all territories outside of North America and Japan, in exchange for milestone payments and royalties based on future partnering and commercial success.

    Santhera thus effectively regains worldwide rights to the drug, including the freedom to license the program to a third party. The new deal does include a call option allowing Ipsen, under certain circumstances, to obtain an exclusive, worldwide license itself, in return for milestone and royalty payments.

    Fipamezole is a selective adrenergic alpha-2 receptor antagonist, which is in development for managing levodopa-induced dyskinesia in Parkinson disease patients. Santhera has already successfully completed two Phase II trials demonstrating the efficacy and safety of the drug. However, the firm admits fipamezole won’t be top of its development priorities list.

    “In the short term, the focus of our investments remains on our lead product Catena® and its multiple product opportunities in neuromuscular and mitochondrial orphan indications,” remarks Thomas Meier, Santhera CEO. “However, fipamezole continues to be a valuable asset in Santhera’s late-stage clinical pipeline.”

    Santhera and Ipsen signed their original fipamezole deal back in September 2010. With €13 million up front, Ipsen obtained rights to fipamezole outside the U.S., Canada, and Japan.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »